ClinicalTrials.gg
CompletedNCT06836037Updated Feb 21, 2025

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

A Phase 1 interventional study of Efinopegdutide and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.
  • Registered 2 years 5 months after the study started (first participant enrolled Sep 2022, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

The goal of this study is to learn about the safety and whether people tolerate a study medicine called efinopegdutide. The study will also measure what happens to efinopegdutide in a healthy person's body over time.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) ≥25 and ≤35 kg/m\^2

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Had major surgery, donated or lost approximately 400 mL blood within 4 weeks prior to entering the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Efinopegdutide Low Dose

    Participants receive low dose efinopegdutide at a single dose on day 1

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide Medium dose

    Participants receive medium dose efinopegdutide at a single dose on day 1

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide High Dose

    Participants receive high dose efinopegdutide at a single dose on day 1

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide Multiple Dose

    Participants receive multiple doses of efinopegdutide over 78 days

    Drug: Efinopegdutide

  • Placebo comparator
    Placebo

    Participants receive placebo to match efinopegdutide dose and regimen

    Drug: Placebo

Interventions

  • Subcutaneous injection

    Also known as: MK-6024, HM12525A, JNJ-64565111,

  • DrugPlacebo

    placebo matching efinopegdutide

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 112 days

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 78 days

  3. Maximum Plasma Concentration (Cmax) of Efinopegdutide- single dose

    Blood samples will be collected to determine the Cmax of efinopegdutide when administered as a single dose

    Time frame: At designated time points up to 35 days

  4. Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- single dose

    Blood samples will be collected to determine the Tmax of efinopegdutide when administered as a single dose

    Time frame: At designated time points up to 35 days

  5. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide- single dose

    Blood samples will be collected to determine the AUC0-last of efinopegdutide when administered as a single dose

    Time frame: At designated timepoints up to 35 days

  6. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of Efinopegdutide- single dose

    Blood samples will be collected to determine the AUC0-inf of efinopegdutide when administered as a single dose

    Time frame: At designated timepoints up to 35 days

  7. Terminal half life (t1/2) of Efinopegdutide- single dose

    Blood samples will be collected to determine the t1/2 of efinopegdutide when administered as a single dose

    Time frame: At designated timepoints up to 35 days

  8. Apparent Clearance (CL) of Efinopegdutide- single dose

    Blood samples will be collected to determine the CL of efinopegdutide when administered as a single dose

    Time frame: At designated timepoints up to 35 days

  9. Volume of Distribution (Vz) of Efinopegdutide- single dose

    Blood samples will be collected to determine the Vz of efinopegdutide when administered as a single dose

    Time frame: At designated timepoints up to 35 days

  10. Maximum Plasma Concentration (Cmax) of Efinopegdutide- multiple dose

    Blood samples will be collected to determine the Cmax of efinopegdutide when multiple doses are administered

    Time frame: At designated time points up to 112 days

  11. Minimum Plasma Concentration (Cmin) of Efinopegdutide- multiple dose

    Blood samples will be collected to determine the Cmin of efinopegdutide when multiple doses are administered

    Time frame: At designated time points up to 112 days

  12. Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- multiple dose

    Blood samples will be collected to determine the Tmax of efinopegdutide when multiple doses are administered

    Time frame: At designated time points up to 112 days

  13. Terminal half life (t1/2) of Efinopegdutide- multiple dose

    Blood samples will be collected to determine the t1/2 of efinopegdutide when multiple doses are administered

    Time frame: At designated timepoints up to 112 days

  14. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide-multiple dose

    Blood samples will be collected to determine the AUC0-last of efinopegdutide when multiple doses are administered

    Time frame: At designated timepoints up to 112 days

  15. Apparent Clearance (CL) of Efinopegdutide- multiple dose

    Blood samples will be collected to determine the CL of efinopegdutide when multiple doses are administered

    Time frame: At designated timepoints up to 112 days

  16. Volume of Distribution at Steady State (Vss) of Efinopegdutide- multiple dose

    Blood samples will be collected to determine the Vss of efinopegdutide when multiple doses are administered

    Time frame: At designated timepoints up to 112 days

  17. Area Under the Concentration-Time Curve to the end of the dosing period (AUC 0-tau)of Efinopegdutide- multiple dose

    Blood samples will be collected to determine the AUC0 to tau of efinopegdutide when multiple doses are administered

    Time frame: At designated timepoints up to 78 days

Secondary outcomes

  1. Change from Baseline in Weight

    Change from baseline in weight will be computed for participants who received multiple doses of efinopegdutide

    Time frame: Baseline and day 112

  2. Change from Baseline in HDL Cholesterol

    Change from baseline in HDL cholesterol will be computed for participants who received multiple doses of efinopegdutide

    Time frame: Baseline and day 112

  3. Change from Baseline in LDL Cholesterol

    Change from baseline in LDL cholesterol will be computed for participants who received multiple doses of efinopegdutide

    Time frame: Baseline and day 112

  4. Change from Baseline in Total Cholesterol

    Change from baseline in total cholesterol will be computed for participants who received multiple doses of efinopegdutide

    Time frame: Baseline and day 112

  5. Change from Baseline in Triglycerides

    Change from baseline in triglycerides will be computed for participants who received multiple doses of efinopegdutide

    Time frame: Baseline and day 112

  6. Number of participants with anti drug antibodies (ADA) to efinopegdutide

    Blood samples will be collected to determine the number of participants with ADA to efinopegdutide

    Time frame: At designated timepoints up to 112 days

07

Study locations

1 site
  • Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001)
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Feb 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 20, 2025
StartActual
Sep 5, 2022
Primary completionActual
Feb 2, 2023
CompletionActual
Feb 2, 2023
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06836037
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Sep 5, 2022
Primary completion
Feb 2, 2023
Completion
Feb 2, 2023
Last update
Feb 21, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion